The impact of octreotide in experimental proliferative vitreoretinopathy

Indian Journal of Ophthalmology

Volumn 61, Issue 3, 2013, Pages 109-114

  Evren, Ozge ^a   Turgut, Burak ^a   Celiker, Ulku ^a   Ates, Kadir ^b  

^a FIRAT UNIVERSITY   (Turkey)

^b FIRAT UNIVERSITY   (Turkey)

Author keywords

Insulin like growth factor 1; octreotide; platelet derivated growth factor; proliferative vitreoretinopathy; transforming growth factor

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CYTOKINE; OCTREOTIDE;

ANIMAL; ARTICLE; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GUINEA PIG; INTRAVITREAL DRUG ADMINISTRATION; METABOLISM; PATHOLOGY; RETINA; TREATMENT OUTCOME; VITREORETINOPATHY;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CYTOKINES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GUINEA PIGS; INTRAVITREAL INJECTIONS; OCTREOTIDE; RETINA; TREATMENT OUTCOME; VITREORETINOPATHY, PROLIFERATIVE;

EID: 84876240188     PISSN: 03014738     EISSN: 19983689     Source Type: Journal    
DOI: 10.4103/0301-4738.109380     Document Type: Article

References (56)

1. Glaser BM, Lemor M. Pathobiology of Proliferative Vitreoretinopathy. In: Ryan SJ, editor. Retina. 2nd ed. St Lous: CV Mosby; 1994. p. 2249-63.
2. Miller B, Miller H, Patterson R, Ryan SJ. Effect of the vitreous on retinal wound-healing. Graefes Arch Clin Exp Ophthalmol 1986;224:576-9.
3. Peyman GA, Shulman JA. Vitreous Substitutes. East Norwalk: Appleton and Lange; 1995.
4. Scott JD. Pathogenesis of prolifeative vitreoretinopathy with analisis of events leading to recurrent retinal detachment. In: Heimann K, Wiedemann P, editors. Proliferative Vitreoretinopathy. Heilderberg: Kaden; 1989. p. 150-3.
5. Weller M, Wiedemann P, Heimann K. Proliferative Vitreoretinopathy. Is it anything more than wound healing at the wrong place? Int Ophthalmol 1990;14:105-17.
6. Wiedemann P, Weller M. The Pathophysiology of proliferative vitreoretinopathy. Acta Ophtalmol Suppl 1988;189:3-15.
7. Charteris DG, Sethi CS, Lewis GP, Fisher SK. Proliferative vitreoretinopathy-developments in adjunctive treatment and retinal pathology. Eye (Lond) 2002;16:369-74.
8. Charteris DG. Proliferative vitreoretinopathy: Pathobiology, surgical management and adjunctive treatment. Br J Ophthalmol 1995;79:953-60.
9. Ezzat S, Mehmed S. Are Patients with acromegaly at increased risk for neoplasia J Clin Endocrinol Metab 1991;72:245-9.
10. Spraul CW, Kawen CK, Kampmeier JK, Lang GK, Lang GE. Effect of thalidomide, octreotide, and prednisolone on the migration and proliferation of RPE cells in vitro. Curr Eye Res 1999;19:483-90.
11. Baldysiak-Figiel A, Lang GK, Kampmeier J, Lang GE. Octreotide prevents growth factor induced proliferation of bovine retinal endothelial cells under hypoxia. Journal of Endocrinology 2004;180:417-24.
12. Cool DE, Andreassen PR, Tonks NK, Krebs EG, Fischer EH, Morgolis RL. Cytokinetic failure and asynchronous nuclear division in BHK cells overexpressing a truncated protein-tyrosinephosphates. Proc Natl Acad Sci 1992;89:5422-6.
13. Grant MB, Wargovich TJ, Ellis EA, Caballero BS, Mansour M, Pepine CJ. Localization of insulin-like growth factor-I and inhibition of coronary smooth muscle cell growth by somatostatin analogues in human coronary smooth muscle cells. Circulation 1994;89:1511-7.
14. Luo Q, Peyman GA, Conway MD, Woltering EA. Effect of somatostatin analog (octreotide acetate) on the growth of retinal pigment epithelial cells in culture. Curr Eye Res 1996;15:909-13.
15. Mallet B, Vialettes B, Haroche S, Escoffier P, Gastaut P. Stabilization of severe proliferative diabetic retinopathy by long-term treatment with SMS 201-995. Diabet and Metabolism 1992;18:438-44.
16. Casani G, Catalani E, Dal Monte M, Bagnoli P. Functional aspects of the somatostatinergic system in the retina and the potential therapeutic role of somatostatin in retinal disease. Histol Histopathol 2005;20:615-32.
17. Qu Y, Zhang S, Xu X, Wang H, Li J, Zhou F, et al. Octreotide inhibits choroidal neovascularization in rats. Ophthalmic Res 2009;42:36-42.
18. Spraul CW, Baldysiak-Figiel A, Lang GK, Lang GE. Octreotide inhibits growth factor-induced bovine choriocapillary endothelial cells in vitro. Graefes Arch Clin Exp 2002;240:227-31.
19. Meng RH, Yang L, Sun L, Zhang WY. The experimental study of octreotide suppressing retinal neovascularization. Zhonghua Yan Ke Za Zhi 2005;41:423-7.
20. Weill CL. Somatostatin prevents natural motoneuron cell death in embriyonic chick spinal cord. Dev Neurosci 1991;13:377-81.
21. Celiker U, Ilhan N, Ozercan I, Demir T, Celiker H. Octreotide reduces ischaemia-reperfusion injury in the retina. Acta Ophthalmol Scand 2002;80:395-400.
22. Celiker U, Ilhan N. Nitric oxide and octreotide in retinal ischemiareperfusion injury. Doc Ophthalmol 2002;105:327-38.
23. Krassas GE, Dumas A, Pontikides N, Kaltsas T. Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease. Clin Endocrinol Oxf 1995;42:571-80.
24. Schultz G, Khaw PT, Oxford K, MaCauley S, Van Setten G, Chegini N. Growth factors and ocular wound healing. Eye (Lond) 1994;8:184-7.
25. Baudouin C, Fredj-Reygrobellet D, Brignole F, Negre F, Lapalus P, Gastaud P. Growth factors in vitreous and subretinal fluid cells from patients with proliferative vitreoretinopathy. Ophthalmic Res 1993;25:52-9.
26. Pfeffer BA, Flanders KC, Guerin CJ, Danielpour D, Anderson DH. Transforming growth factor beta 2 is the predominant isoform in the neural retina, retinal pigment epithelium-choroid and vitreous of the monkey eye. Exp Eye Res 1994;59:323-3.
27. Bornstein P. Thrombospondins as matricelllular modulators of cell function. J Clin Invest 2001;107:929-34.
28. Hinton DR, He S, Jin ML, Barron E, Ryan SJ. Novel growth factors involved in the pathogenesis of proliferative vitreoretinopathy. Eye (Lond) 2002;16:422-8.
29. Jester JV, Huang J, Petroll WM, Cavanagh HD. TGF beta induced myofibroblast differentiation of rabbit keratocytes requires synergistic TGF beta, PDGF and integrin signaling. Exp Eye Res 2002;75:645-57.
30. Hinton DR, He S, Graf K, Yang D, Hsueh WA, Ryan SJ, et al. Mitogen activated protein kinase activation mediates PDGF directed migration of RPE cells. Exp Cell Res 1998;239:11-5.
31. Limb GA, Hollifield RD, Webster L, Charteris DG, Chignell AH. Soluble TNF receptors in vitreoretinal proliferative disease. Invest Opthalmol Vis Sci 2001;42:1586-91.
32. Campochiaro PA, Sugg R, Grotendorst G, Hjelmeland LM. Retinal pigment epithelial cells produce PDGF-like proteins and secrete them into their media. Exp Eye Res 1989;49: 217-27.
33. Andrews A, Balciunaite E, Leong FL, Tallquist M, Soriano P, Refojo M, et al. Platelet-derived growth factor plays a key role in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1999;40:2683-9.
34. Ikuno Y, Leong FL, Kazlauskas A. Attenuation of experimental proliferative vitreoretinopathy by inhibiting the plateletderived growth factor receptor. Invest Opthalmol Vis Sci 2000; 41:3107-16.
35. Seo MS, Okamoto N, Vinores MA, Vinores SA, Hackett SF, Yamada H, et al. Photoreceptor-specific expression of plateletderived growth factor-B results in traction retinal detachment. Am J Pathol 2000;157:995-1005.
36. Hardwick C, Feist R, Morris R, White M, Angus R, Guidry C. Tractional force generation by porcine muller cells stimulation by growth factors in human vitreous. Invest Ophthalmol Vis Sci 1997;38:2053-63.
37. Smith LE, Shen W, Perruzzi C, Soker S, Kinose F, Xu X, et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med 1999;5:1390-5.
38. Guidry C, Mamballikalathil I, Mann C. Tractional force generation by porcine muller cells development and differential stimulation by growth factors. Invest Ophthalmol Vis Sci 1997;38:456-68.
39. Frenzel E, Neely KA, Walsh AW, Cameron JD. A new model of proliferativevitreoretinopathy. Invest Ophthalmol Vis Sci 1998;39:2157-64.
40. Cantó Soler MV, Gallo JE, Dodds RA, Suburo AM. A mouse model of proliferative vitreoretinopathy induced by dispase. Exp Eye Res 2002;75:491-504.
41. Liang C, Peyman GA, Conway MD, Woltering EA. Retinal toxicity of intravitreous octreotide in the rabbit. Can J Ophthalmol 1997;32:229-32.
42. Robertson JE, Westra I, Woltering EA, Winthrop KL, Barrie R, O'Dorisio TM, et al. Intravitreal injection of octreotide acetate. J Ocul Pharmacol Ther 1997;13:171-7.
43. Stern WH, Guerin CJ, Erickson PA, Levvis GP, Anderson DH, Fisher SK. Ocular toxicity of fluorouracil after vitrectomy. Am J Ophthalmol 1983;96:43-51.
44. Steinhorst UH, Hatchell DL, Chen EP, Machemer R. Ocular toxicity of daunomycin: Effects of subdivided doses on the rabbit retina after vitreous gas compression. Graefe's Arch Clin Exp Ophthalmol 1993;231:591-4.
45. Imai K, Loevvenstein A, Koroma B, Grebe R, de Juan EJ. Herbimycin A in the treatment of experimental proliferative vitreoretinopathy: Toxicity and efficacy studies. Graefes Arch Clin Exp Ophthalmol 2000;238:440-7.
46. Günal AI, Duman S, Sen S, Unsal A, Terzio-lu E, Akçiç ek F, et al. By reducing TGF beta 1, octreotide lessens the peritoneal derangements induced by a high glucose solution. J Nephrol 2001;14:184-9.
47. Ryan SJ. The pathophysiology of proliferative vitreoretinopathy in its management. Am J Ophthalmol 1985;100:188-93.
48. Pastor JC, de la Rua ER, Martin F. Proliferative vitreoretinopathy: Risk factors and pathobiology. Prog Ret Eye Res 2002;21:127-44.
49. Chen F, O'Dorisio MS, Hermann G, Hayes J, Malarkey WB, O'Dorisio TM. Mechanisms of action of long-acting analogs of somatostatin. Regul Pept 1993;44:285-95.
50. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996;334:246-54.
51. Mukherjee S, Guidry C. The Insulin-Like Growth Factor System Modulates Retinal Pigment Epithelial Cell Tractional Force Generation. Invest Ophthalmol Vis Sci 2007;48:1892-9.
52. Günal AI, I-ik A, Celiker H, Eren O, Celebi H, Günal SY, et al. Short term reduction of ventricular mass in primary hypertrophic cardiomyopathy by octreotide injections. Heart 1996;76:418-21.
53. Cunliffe IA, Rees RC, Rennie, IG. The effect of TGF-beta 1 and TGFbeta 2 on the proliferation of human Tenon's capsule fibroblasts in tissue culture. Acta Ophthalmol Scand 1996;74:31-5.
54. Cordeiro MF, Gay JA, Khaw PT. Human anti-transforming growth factor-beta2 antibody: A new glaucoma anti-scarring agent. Invest Ophthalmol Vis Sci 1999;40:2225-34.
55. Demir T, Turgut B, Celiker U, Ozercan I, Ulas F, Akyol N. Effects of octreotide acetate and amniotic membrane on wound healing in experimental glaucoma surgery. Doc Ophthalmol 2003;107:87-92.
56. Amann J, Kaven C, Spraul CW, Lang GK, Lang GE. Effect of octreotide combined with growth factors on proliferation of RPE cells in vitro. Ophthalmologe 2000;97:737-41.